Table 1.
Summary of AXL immunostaining in patient LPS samples
| Histology | Patients (n) | Samplesc (n) | Positive for AXL immunostain | |
|---|---|---|---|---|
| Patients (%) (n = 83) | Samples (%) (n = 104) | |||
| NF | 12 | 12 | 0 (0) | 0 (0) |
| LPS (Total) | 83 | 104 | 23 (27.7) | 27 (26.0) |
| LPS subtype | ||||
| WDLPS | ||||
| Extremity | 3 | 3 | - | - |
| Retroperitoneum | 31 | 43 | 7 (22.6) | 7 (16.3) |
| Total | 34 | 46 | 7 (20.6) | 7 (15.2) |
| DDLPS | ||||
| Extremity | 1 | 1 | - | - |
| Retroperitoneum | 17 | 18 | 4 (23.5) | 4 (22.2) |
| Total | 18 | 19 | 4 (22.2) | 4 (21.1) |
| PLS | ||||
| Extremity | 23 | 29 | 10 (43.5) | 11 (37.9) |
| Retroperitoneum | 2 | 2 | - | - |
| Other a,b | 7 | 8 | 2 (28.6) | 3 (37.5) |
| Total | 31 | 39 | 12 (37.5) | 14 (35.9) |
aOne patient with PLS had a primary tumor in the extremity as well as a metastatic lesion in the lung which was included on the TMA. Therefore, the total number of PLS patients is 31, not 32
bOther locations include lung (n = 4 patients, 5 samples) and chest/back (n = 3 patients, 3 samples)
cSeveral patients had multiple tumor samples included on the TMA